Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United States Oil ETF (USO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs United States Oil ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while United States Oil ETF trades at $112.91. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | USO | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $152.96 |
52-Week Low | $20.06 | $66.17 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
USO (United States Oil Fund) trades at $104.35, showing modest daily gains of 0.36% amid heightened geopolitical tensions in the Middle East. Technical indicators signal a bearish trend with moving averages showing strong sell signals, though oscillators remain neutral. The fund's price action reflects direct exposure to crude oil volatility, with recent U.S. military strikes against Iran and attacks in the Strait of Hormuz driving supply disruption fears and price increases.
The outlook remains heavily dependent on geopolitical developments and oil supply dynamics. While recent Middle East tensions provide upward price pressure, risks include potential supply increases from Gulf producers and weak demand signals that could limit sustained recovery. The fund offers direct commodity exposure but faces contango risks and tracking error inherent to futures-based ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
